Last reviewed 2026-04-19 · How we verify

P1101 180 µg Q1W, 48 doses

PharmaEssentia · Phase 2 active Biologic

P1101 180 µg Q1W, 48 doses is a Biologic drug developed by PharmaEssentia. It is currently in Phase 2 development.

At a glance

Generic name	P1101 180 µg Q1W, 48 doses
Sponsor	PharmaEssentia
Modality	Biologic
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Dose Finding Study of Pegylated-P-Interferon-alpha-2b(P1101) in Treatment-Naive Subjects With Hepatitis C Virus Genotype 1 Infection (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

P1101 180 µg Q1W, 48 doses CI brief — competitive landscape report
P1101 180 µg Q1W, 48 doses updates RSS · CI watch RSS
PharmaEssentia portfolio CI

Frequently asked questions about P1101 180 µg Q1W, 48 doses

What is P1101 180 µg Q1W, 48 doses?

P1101 180 µg Q1W, 48 doses is a Biologic drug developed by PharmaEssentia.

Who makes P1101 180 µg Q1W, 48 doses?

P1101 180 µg Q1W, 48 doses is developed by PharmaEssentia (see full PharmaEssentia pipeline at /company/pharmaessentia).

What development phase is P1101 180 µg Q1W, 48 doses in?

P1101 180 µg Q1W, 48 doses is in Phase 2.

Manufacturer: PharmaEssentia — full pipeline
Compare: P1101 180 µg Q1W, 48 doses vs similar drugs
Pricing: P1101 180 µg Q1W, 48 doses cost, discount & access